Abstract:The European Directive 2004/24/EC introducing a simplified registration procedure for traditional herbal medicinal products, plays an important role in harmonising the current legislation framework for all herbal medicinal products in the European Union (EU). Although substantial achievements have been made under the new scheme, only a limited number of herbal medicinal products from non-European traditions commonly used in Europe have been registered. Therefore, identification of the obstacles, and determination of appropriate means to overcome the major challenges in the registration of non-European traditional herbal medicinal products are of critical importance for the EU herbal medicinal product market. The primary aims of this study were to understand the key issues and obstacles to registration of non-European traditional herbal medicinal products within the EU. The findings may identify the need for more attention on the Community herbal monographs elaborated by the Herbal Medicinal Products Committee (HMPC), as well as further evidence based scientific research on non-European herbal substances/preparations by the scientific community. A systematic evaluation of the herbal substances and preparations included in Community herbal monographs and public statements has been carried out. The focus was herbal substances and preparations derived from non-European traditions. Of the 109 adopted Community herbal monographs, 10 are herbal substances used in Chinese traditional medicine. Where the HMPC issued a public statement because it was unable to elaborate a monograph more than half-involved herbal substances/preparations from non-European traditions. The main reasons herbal substances/preparations from non-European traditions were not accepted for inclusion in the Community herbal monographs have been identified as due to unfulfilled requirements of Directive 2004/24/EC. The most common reasons were the lack of evidence to demonstrate a 15-year minimum medicinal use period in the EU and evidence of absence of health risk as required by Article 16a (1) (d), and Article 16a (1) (e). Under the current EU legislation, the requirement to demonstrate 15-year minimum medicinal use in the EU is a major obstacle to the registration of non-European traditional herbal medicinal products. Access to scientific data to support the product safety profile may be a possible solution to overcome the hurdle presented by the 15-year minimum medicinal use period. Furthermore, the Community herbal monographs play an important role in the registration process. Therefore, making full use of existing Community herbal monographs, and promoting scientific research and subsequent development of additional monographs for herbal substances and preparations, and combinations thereof from non-European traditions would be of benefit to herbal medicinal product registration from non-European traditions.

Comparison of the Requirements for Pre-clinical Safety Evaluation of Compound Traditional Chinese Medicine and European Union Compound Herbs

Comparison of the guidelines on good agricultural and collection practices in herbal medicine of the European Union, China, the WHO, and the United States of America

Key quality factors for Chinese herbal medicines entering the EU market

Research Progress on Quality Control Methods for Xiaochaihu Preparations

A Legal Analysis on the Current Trade Status of Traditional Chinese Medicinal Product in the E.U. — From the Perspectives of WTO Law and E.U. Pharmaceutical Law

Quality Standard of Traditional Chinese Medicines: Comparison Between European Pharmacopoeia and Chinese Pharmacopoeia and Recent Advances

Comparison Study of Western Medical service versus Eastern medical service : Trade Barriers on Traditional Chinese Medicine in Europe

Progression on Studies of Effective Components of Chinese Herbal Compound

Comparision and analysis on the blood concentration of common Chinese medicine and Western medicine

The rise of traditional Chinese medicine and its materia medica: A comparison of the frequency and safety of materials and species used in Europe and China

Impact of Chinese Herbal Medicine on American Society and Health Care System: Perspective and Concern

[Evaluation for druggability of traditional Chinese medicine preparations in medical institutions based on human use experience]

Current Status and Major Challenges to the Safety and Efficacy Presented by Chinese Herbal Medicine

The rise of Traditional Chinese Medicine and its materia medica : a comparison of frequency and safety of materials and species used in Europe and China

'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors

Non-European Traditional Herbal Medicines in Europe: a Community Herbal Monograph Perspective.

Characterization and Comparison Analysis of WHO Monographs on Selected Medicinal Plants and ISO Standards of Chinese Materia Medica

Assessment of Pharmacodynamics of Compound Preparations Made of Two Chinese Medicinal Herbes and Pharmacokinetics of Their Tested Components -and a Discussion on Study Method of Pharmacokinetics of Traditional Chinese Medicine

Process and Key Points of Clinical Literature Evaluation of Post-Marketing Traditional Chinese Medicine

[Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version)]

[Comparative Study on the Original Plant Differences of Chinese Traditional Medicines and Japanese Kampo Medicines].